IFITM2
IFITM2 (Interferon Induced Transmembrane Protein 2) is a Protein Coding gene. Diseases associated with IFITM2 include Influenza and Dengue Virus. Among its related pathways are Cytokine Signaling in Immune system and Innate Immune System. An important paralog of this gene is IFITM3.
Full Name
Interferon Induced Transmembrane Protein 2
Function
IFN-induced antiviral protein which inhibits the entry of viruses to the host cell cytoplasm, permitting endocytosis, but preventing subsequent viral fusion and release of viral contents into the cytosol (PubMed:33563656, PubMed:26354436).
Active against multiple viruses, including influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2), Marburg virus (MARV), Ebola virus (EBOV), Dengue virus (DNV), West Nile virus (WNV), human immunodeficiency virus type 1 (HIV-1), hepatitis C virus (HCV) and vesicular stomatitis virus (VSV) (PubMed:33563656, PubMed:26354436, PubMed:33270927, PubMed:33239446).
Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry, SARS-CoV and SARS-CoV-2 S protein-mediated viral entry and VSV G protein-mediated viral entry (PubMed:33563656).
Induces cell cycle arrest and mediates apoptosis by caspase activation and in p53-independent manner. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation (PubMed:26354436).
IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome (PubMed:26354436).
Active against multiple viruses, including influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2), Marburg virus (MARV), Ebola virus (EBOV), Dengue virus (DNV), West Nile virus (WNV), human immunodeficiency virus type 1 (HIV-1), hepatitis C virus (HCV) and vesicular stomatitis virus (VSV) (PubMed:33563656, PubMed:26354436, PubMed:33270927, PubMed:33239446).
Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry, SARS-CoV and SARS-CoV-2 S protein-mediated viral entry and VSV G protein-mediated viral entry (PubMed:33563656).
Induces cell cycle arrest and mediates apoptosis by caspase activation and in p53-independent manner. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation (PubMed:26354436).
IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome (PubMed:26354436).
Biological Process
Cellular response to interferon-beta Source: UniProtKB
Defense response to virus Source: GO_Central
Immune response Source: ProtInc
Negative regulation of viral entry into host cell Source: UniProtKB
Negative regulation of viral genome replication Source: UniProtKB
Response to interferon-alpha Source: UniProtKB
Response to interferon-beta Source: UniProtKB
Response to interferon-gamma Source: UniProtKB
Response to virus Source: UniProtKB
Type I interferon signaling pathway Source: GO_Central
Defense response to virus Source: GO_Central
Immune response Source: ProtInc
Negative regulation of viral entry into host cell Source: UniProtKB
Negative regulation of viral genome replication Source: UniProtKB
Response to interferon-alpha Source: UniProtKB
Response to interferon-beta Source: UniProtKB
Response to interferon-gamma Source: UniProtKB
Response to virus Source: UniProtKB
Type I interferon signaling pathway Source: GO_Central
Cellular Location
Late endosome membrane; Lysosome membrane; Cell membrane
Topology
Cytoplasmic: 1-56
Helical: 57-77
Cytoplasmic: 78-106
Helical: 107-127
Extracellular: 128-132
Helical: 57-77
Cytoplasmic: 78-106
Helical: 107-127
Extracellular: 128-132
PTM
Palmitoylation on membrane-proximal cysteines controls clustering in membrane compartments and antiviral activity.
Phosphorylation at Tyr-19 is required for endosomal and lysosomal location.
Phosphorylation at Tyr-19 is required for endosomal and lysosomal location.
View more
Anti-IFITM2 antibodies
+ Filters
Loading...
Target: IFITM2
Host: Mouse
Antibody Isotype: IgG1
Specificity: Human
Clone: A386
Application*: ELISA, WB
Target: IFITM2
Host: Mouse
Antibody Isotype: IgG2a, κ
Specificity: Human
Clone: 1F2
Application*: WB, E
Target: IFITM2
Host: Mouse
Antibody Isotype: IgG1
Specificity: Human
Clone: CF213
Application*: ELISA, WB, FC
More Infomation
Hot products 
-
Mouse Anti-CCN2 Recombinant Antibody (CBFYC-2383) (CBMAB-C2456-FY)
-
Mouse Anti-CD33 Recombinant Antibody (P67.6) (CBMAB-C10189-LY)
-
Mouse Anti-BrdU Recombinant Antibody (IIB5) (CBMAB-1038CQ)
-
Mouse Anti-APP Recombinant Antibody (5C2A1) (CBMAB-A3314-YC)
-
Mouse Anti-BACE1 Recombinant Antibody (61-3E7) (CBMAB-1183-CN)
-
Mouse Anti-C5b-9 Recombinant Antibody (aE11) (CBMAB-AO138LY)
-
Mouse Anti-AGK Recombinant Antibody (V2-258056) (CBMAB-M0989-FY)
-
Rat Anti-CD63 Recombinant Antibody (7G4.2E8) (CBMAB-C8725-LY)
-
Mouse Anti-ENO2 Recombinant Antibody (85F11) (CBMAB-0276CQ)
-
Mouse Anti-ACE2 Recombinant Antibody (V2-179293) (CBMAB-A0566-YC)
-
Rat Anti-(1-5)-α-L-Arabinan Recombinant Antibody (V2-501861) (CBMAB-XB0003-YC)
-
Mouse Anti-AFM Recombinant Antibody (V2-634159) (CBMAB-AP185LY)
-
Mouse Anti-ACLY Recombinant Antibody (V2-179314) (CBMAB-A0610-YC)
-
Mouse Anti-DMD Recombinant Antibody (D1190) (CBMAB-D1190-YC)
-
Rat Anti-4-1BB Recombinant Antibody (V2-1558) (CBMAB-0953-LY)
-
Mouse Anti-CD247 Recombinant Antibody (6B10.2) (CBMAB-C1583-YY)
-
Mouse Anti-CD164 Recombinant Antibody (CBFYC-0077) (CBMAB-C0086-FY)
-
Mouse Anti-ENO1 Recombinant Antibody (CBYC-A950) (CBMAB-A4388-YC)
-
Mouse Anti-ADV Recombinant Antibody (V2-503423) (CBMAB-V208-1364-FY)
-
Rat Anti-CD300A Recombinant Antibody (172224) (CBMAB-C0423-LY)
For Research Use Only. Not For Clinical Use.
(P): Predicted
* Abbreviations
- AActivation
- AGAgonist
- APApoptosis
- BBlocking
- BABioassay
- BIBioimaging
- CImmunohistochemistry-Frozen Sections
- CIChromatin Immunoprecipitation
- CTCytotoxicity
- CSCostimulation
- DDepletion
- DBDot Blot
- EELISA
- ECELISA(Cap)
- EDELISA(Det)
- ESELISpot
- EMElectron Microscopy
- FFlow Cytometry
- FNFunction Assay
- GSGel Supershift
- IInhibition
- IAEnzyme Immunoassay
- ICImmunocytochemistry
- IDImmunodiffusion
- IEImmunoelectrophoresis
- IFImmunofluorescence
- IGImmunochromatography
- IHImmunohistochemistry
- IMImmunomicroscopy
- IOImmunoassay
- IPImmunoprecipitation
- ISIntracellular Staining for Flow Cytometry
- LALuminex Assay
- LFLateral Flow Immunoassay
- MMicroarray
- MCMass Cytometry/CyTOF
- MDMeDIP
- MSElectrophoretic Mobility Shift Assay
- NNeutralization
- PImmunohistologyp-Paraffin Sections
- PAPeptide Array
- PEPeptide ELISA
- PLProximity Ligation Assay
- RRadioimmunoassay
- SStimulation
- SESandwich ELISA
- SHIn situ hybridization
- TCTissue Culture
- WBWestern Blot
Online Inquiry




